 Home > Active Ingredient News > Diagnostic Test > Bristol-Myers Squibb partners with Xencor to extend COVID-19 antibody half...

Bristol-Myers Squibb partners with Xencor to extend COVID-19 antibody half...

 Last Update: 2021-06-03
 Source: Internet
 Author: User

Tags

use hand sanitizer

antimicrobial treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

A few days ago, Xencor and Bristol Myers Squibb (Bristol Myers Squibb) signed a license agreement for the use of Xtend XmAb technology.

Bristol-Myers Squibb’s progress in the treatment of COVID-19 has been relatively slow.

SARS-CoV-2 mAb Duo was originally discovered by researchers at Rockefeller University.

Bristol-Myers Squibb plans to quickly enter the registration study after the completion of the first phase.

According to the terms of the agreement, Bristol-Myers Squibb will be solely responsible for supporting and advancing the research, development, regulatory application and commercial activities of SARS-CoV-2 mAb Duo.

The progress of the Bristol-Myers Squibb antibody portfolio is far behind that of companies such as Eli Lilly and Regeneron, which have similar treatment methods.

The FDA also revoked the emergency use authorization of bamlanivimab monotherapy.

Reference source:

2.
Bristol Myers Squibb: Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Bristol-Myers Squibb partners with Xencor to extend COVID-19 antibody half-life

07-06

Related Products

Sodium diatrizoate hydrate 99.00% White powder AsiaChem

CAS No.: 737-31-5

Pharmacy Grade

$442-450/KG FOB

3,5-Diacetamido-2,4,6-triiodobenzoic acid 99% 50978-11-5 white powder silworld

CAS No.: 50978-11-5

$500-520/KG FOB

Barium Sulphate

CAS No.: 13462-86-7

Industrial Grade

$3/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Bristol-Myers Squibb partners with Xencor to extend COVID-19 antibody half...

Related Articles

Bristol-Myers Squibb partners with Xencor to extend COVID-19 antibody half-life